Right now, every Tesla car is made right here in the United States — and specifically in California.
This, however, is about to change…
Naturally, these cars are sold to other countries as well, and that includes places that don’t manufacture them. Just this year, Tesla sold over 3,000 of its cars in China.
So, it only makes sense that Tesla’s going to start manufacturing its product in China, just like other global car makers.
You might have even caught Elon Musk’s recent remarks that Tesla could start producing cars in China as soon as two years from now.
That certainly bodes well for consumers, considering that it’ll cut retail prices by about a third.
In fact, Tesla is already working with Baidu — a major Internet company in China — to improve the cars’ navigation and automated driving features.
Battery production won’t be an issue by then, as the Gigafactory in Nevada is slated to start producing its lithium-ion batteries next year, and will likely be operating at full capacity in roughly two or three years.
That is perfect timing for the manufacturing of these cars in China.
The goal, obviously, is to market the product to as many people as possible. With only one production plant, that may as well be impossible.
Having a plant in China opens the theoretical door of opportunity. The product will reach a greater number of consumers than ever before.
To continue reading…
Until next time,
A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.
For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.
Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.